Jonathan S Leff
CIK 1215242 · last filed 2026-05-20
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ISPH price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
780 THIRD AVENUE, 37TH FLOOR
NEW YORK, NY 10017
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LRMR | Director | — | $2.33 | — | $0 | 7 | 2026-05-20 |
| BiomX Inc. (PHGE) Delisted | Director | — | $1.85 | — | $0 | 2 | 2025-04-21 |
| BiomX Inc. (PHGE.U) Delisted | Director | — | $0.90 | — | $0 | 1 | 2024-07-15 |
| PRTO | Director | — | $27.11 | — | $0 | 2 | 2018-06-12 |
| AveXis, Inc. (AVXS) Delisted | Director | — | — | — | $0 | 1 | 2016-02-12 |
| ALPINE IMMUNE SCIENCES, INC. (NVLS) Delisted | Director | — | — | — | $0 | 2 | 2015-09-15 |
| ALLOS THERAPEUTICS INC (ALTH) Delisted | Director | 26,124,430 | — | — | $19.74M | 8 | 2012-09-05 |
| INSPIRE PHARMACEUTICALS INC (ISPH) Delisted | Director | 0 | — | — | $40.00M | 6 | 2011-05-16 |
| ZYMOGENETICS INC (ZGEN) Delisted | Director | 0 | $12.01 | $0 | $9.54M | 13 | 2010-10-12 |
| NEUROGEN CORP (NRGN) Delisted | Director | 13,571,411 | — | — | $0 | 10 | 2008-07-28 |
| Altus Pharmaceuticals Inc. (ALTU) Delisted | Director | — | $10.12 | — | $0 | 3 | 2008-06-13 |
| Viracta Therapeutics, Inc. (SNSS) Delisted | Director | 3,416 | $18.62 | $63.6K | $3.00M | 3 | 2008-06-05 |
Recent Filings · Page 8 of 8
73 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2007-05-17 | — | Grant (A) | — | $0 | |
| 2007-03-15 | NEUROGEN CORP (NRGN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2007-02-05 | Altus Pharmaceuticals Inc. (ALTU) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.